Cue Biopharma, Inc. (CUE) is a publicly traded Healthcare sector company. As of May 21, 2026, CUE trades at $20.03 with a market cap of $86.50M and a P/E ratio of -16.45. CUE moved -1.53% today. Year to date, CUE is +77.99%; over the trailing twelve months it is +1.70%. Its 52-week range spans $4.97 to $59.67. Rallies surfaces CUE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in CUE news today?
Cue Biopharma Raises $30M, Earns $7.5M Milestone, Licenses CUE-221 and Preps INDs: Cue Biopharma reported first‐quarter revenue of $5.7 million, cut net loss to $5.2 million from $12.3 million and held $16.4 million cash. It secured a $30 million private placement, a $7.5 million milestone payment, licensed CUE-221 and plans IND filings for CUE-221 and CUE-401.
Sarraf Pasha bought 4.23K (~$1.31K) on Dec 30, 2025.
Sarraf Pasha bought 77.15K (~$23.17K) on Dec 30, 2025.
Sarraf Pasha bought 86.95K (~$27.60K) on Dec 30, 2025.
CUE Analyst Consensus
CUE analyst coverage data. Average price target: $0.00.
Common questions about CUE
What changed in CUE news today?
Cue Biopharma Raises $30M, Earns $7.5M Milestone, Licenses CUE-221 and Preps INDs: Cue Biopharma reported first‐quarter revenue of $5.7 million, cut net loss to $5.2 million from $12.3 million and held $16.4 million cash. It secured a $30 million private placement, a $7.5 million milestone payment, licensed CUE-221 and plans IND filings for CUE-221 and CUE-401.
Does Rallies summarize CUE news?
Yes. Rallies summarizes CUE news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is CUE research on Rallies investment advice?
No. Rallies provides research, data, and educational context for CUE. It does not provide personalized investment advice.
